DAPTOMYCIN
| Brand name | CUBICIN |
|---|---|
| Active ingredient | DAPTOMYCIN |
| Strength | 500MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Dosage form | POWDER |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | September 2003 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 8003673 | September 2028 | use U-1180 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.